CX-801 is under development for the treatment of metastatic solid tumors including metastatic melanoma, metastatic renal cell carcinoma (RCC) and head and neck squamous cell carcinoma (HNSCC). It is a ...

HB-0036 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate ...

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a ...

A paper published in the Journal of Clinical Oncology, titled "Comparative Analysis of Intracranial Response Assessment ...

Song Park, MD, University of Washington Medicine, advocates for more user-friendly technology to support equitable skin cancer care access.

Post-treatment evaluations showed that the immunotherapy eliminated 95% of pre-cancerous spots on subjects' faces.

Researchers concluded that dabrafenib and trametinib appeared active in the second-line adjuvant setting, “although more follow up is required to confirm.” ...

CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.

Designation will ease the gene-based breakthrough’s transition from laboratory to clinic with tax breaks and other investment ...

A new study uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment. This therapy is the first to activate specific components of the ...

A new study by investigators from Mass General Brigham uncovers how a novel immunotherapy prevents squamous cell carcinoma, ...

When did you last have a skin check for skin cancer? If you can’t remember, then it was probably too long ago.